Your browser doesn't support javascript.
loading
Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
Chen, Shih-Hsun; Dominik, Pawel K; Stanfield, Jessica; Ding, Sheng; Yang, Wenjing; Kurd, Nadia; Llewellyn, Ryan; Heyen, Jonathan; Wang, Carole; Melton, Zea; Van Blarcom, Thomas; Lindquist, Kevin C; Chaparro-Riggers, Javier; Salek-Ardakani, Shahram.
Afiliação
  • Chen SH; Cancer Immunology Discovery, Pfizer Inc, San Diego, California, USA Shih-Hsun.Chen@pfizer.com javier.chaparro-riggers@pfizer.com ssalekardakani@gmail.com.
  • Dominik PK; BioMedicine Design, Pfizer Inc, San Diego, California, USA.
  • Stanfield J; Cancer Immunology Discovery, Pfizer Inc, San Diego, California, USA.
  • Ding S; BioMedicine Design, Pfizer Inc, San Diego, California, USA.
  • Yang W; Computational Biology, Pfizer Inc, San Diego, California, USA.
  • Kurd N; Cancer Immunology Discovery, Pfizer Inc, San Diego, California, USA.
  • Llewellyn R; Cancer Immunology Discovery, Pfizer Inc, San Diego, California, USA.
  • Heyen J; Drug Safety R&D, Pfizer Inc, San Diego, California, USA.
  • Wang C; BioMedicine Design, Pfizer Inc, San Diego, California, USA.
  • Melton Z; BioMedicine Design, Pfizer Inc, San Diego, California, USA.
  • Van Blarcom T; BioMedicine Design, Pfizer Inc, San Diego, California, USA.
  • Lindquist KC; BioMedicine Design, Pfizer Inc, San Diego, California, USA.
  • Chaparro-Riggers J; BioMedicine Design, Pfizer Inc, San Diego, California, USA Shih-Hsun.Chen@pfizer.com javier.chaparro-riggers@pfizer.com ssalekardakani@gmail.com.
  • Salek-Ardakani S; Cancer Immunology Discovery, Pfizer Inc, San Diego, California, USA Shih-Hsun.Chen@pfizer.com javier.chaparro-riggers@pfizer.com ssalekardakani@gmail.com.
J Immunother Cancer ; 9(10)2021 10.
Article em En | MEDLINE | ID: mdl-34599020
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Antígeno CD47 / Inibidores de Checkpoint Imunológico / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Anticorpos Biespecíficos / Antígeno CD47 / Inibidores de Checkpoint Imunológico / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: J Immunother Cancer Ano de publicação: 2021 Tipo de documento: Article